Home / Faculty / Glenn Francis

Glenn Francis

President of The Australasian Immunohistochemistry Society
Genomics For Life Pty Ltd
3 Hi-Tech Court, Eight Mile Plains,
Queensland 4113, Australia

Dr Glenn Francis graduated from the University of Queensland in 1984 (MBBS Hons) and subsequently trained in general pathology.

Following completion of his training in 1991, he began work in a private pathology laboratory based in Redcliffe. He established a new private laboratory in Rockhampton Central Queensland in 1994 with additional laboratories in Emerald and Townsville. Dr Francis developed an interest in breast and molecular pathology and became Convener of the RCPA Immunohistochemistry Quality Assurance Program (RCPA QAP Pty Ltd) in 2001. In 2002, he relocated to the Gold Coast and was appointed Pathologist in charge of the Gold Coast and Northern Rivers region in a private pathology laboratory. In 2005 he was appointed Director of Pathology Princess Alexandra Hospital Brisbane and established the Molecular and Clinical Pathology Research Laboratory in 2008. In 2011 he was appointed as Medical Director Pathology Queensland Central Laboratory (Royal Brisbane, Women’s and Children’s Hospitals) and initiated the molecular testing program for the RCPA QAP for mutations in EGFR, BRAF and KRAS. In late 2013 he returned to private pathology practice.

Dr Francis has a special interest in molecular patholgy and personalised medicine. His current appointments include Adjunct Associate Professor Australian Institute for Bioengineering and Nanotechnology University of Queensland, President Australasian Immunohistochemistry Society, Molecular Pathology Advisory Board, EGFR IHC Expert Panel, RCPA Tissue Banking Working Party, Assessor for the National Association of Testing Authorities, RCPA General Pathology Advisory Committee and MSAC Expert Standing Panel.

His current research activities include prognostic biomarkers in breast cancer, molecular biology, diagnostic oncology, next generation sequencing, neural network applications in pathology, immunohistochemistry and in-situ hybridization. Collaborative research is being performed in conjunction with the Queensland Institute of Medical Research, University of Queensland, Queensland University of Technology, The Garvan Institute and the Peter MacCallum Cancer Institute.